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102 Poster Session-IIrate, the proportion of these units meeting storage criteria is low.
Of the 448 units collected in this study, only 19.2% met banking
guidelines as compared to 22.0% for Caucasians, 26.7% for
Asians, and 20.0% for Hispanics. African American units not
meeting storage criteria were deferred primarily for low volume
(54.7%) and total nucleated cell count (25.2%). Acknowledging
that biologic factors negatively impact the recovery of nucleated
cells from cord blood collected from this population, the SLCBB
is currently designing a Phase II study to assess alternative
methods to increase collection volumes and cellular yield for
African American donors.279
T-CELL ENGRAFTMENT KINETICS FOLLOWING MYELOABLATIVE AND
NONMYELOABLATIVE REGIMENS FOR ALLOGENEIC HEMATOPOIETIC
TRANSPLANTATION
Mickelson, D.1, Sproat, L.3, Dean, R.2, Sobecks, R.2, Rybicki, L.2,
Kalaycio, M.2, Pohlman, B.2, Sweetenham, J.2, Andresen, S.2,
Bolwell, B.2, Copelan, E.2 1Cleveland Clinic, Cleveland, OH; 2Cleveland
Clinic, Taussig Cancer Institute, Cleveland, OH; 3Cleveland Clinic,
Cleveland, OH
Monitoring of T-cell chimerism after nonmyeloablative(NMA)
regimens has been used to identify patients at risk for graft rejection,
relapse and acute and chronic graft-versus host disease and to deter-
mine use and timing of donor lymphocyte infusions. Followingmye-
loablative (MA) transplantation chimerism studies are not considered
useful because T-cell engraftment is thought to occur rapidly . We
analyzed T-cell engraftment following NMA (fludarabine/TBI)
and after MA transplantation generally busulfan-based. T-cell chi-
merism was studied in 116 patients following MA (busulfan-based
in 72) and 99 patients following NMA transplantation between 5/
2000 and 11/2007, using STR of CD31 cells at 30, 60 and 90 days.
The estimated median interval to T-cells $ 50% donor was 29
days after MA and 27 days after NMA and to T-cells$90% donor
was 42 and 44 days respectively. Comparing only the 72 patients
receiving busulfan based MA preparation to the NMA patients,
T-cell chimerism$10% (p\0.001) and$50% (p5 0.029) occurred
more quickly after NMA transplantation. There was no difference
(p 5 0.68) in the interval to$90% donor T-cells. T-cell
chimerism.50% was associated with more acute GVHD (p 5
0.02), less graft rejection (p\0.001) and less relapse (p5 0.05) follow-
ing NMA regimens, while T-cell chimerism.90% was associated
with more chronic GVHD (p 5 0.002). In MA transplants,
chimerism.50% and .90% were associated with more acute
GVHD (p 5 0.04, p 5 0.009), and chimerism.90% was associated
withmore chronicGVHD (p5 0.07). InNMA,multivariate analysis
found that patients with AML (p5 0.02) and more prior chemother-
apy(p50.04)weremore likely to reach chimerism.50%,while those
with a diagnosis of AML (p5 0.04), MDS (p5 0.002) or CLL (p5
0.05) were more likely to reach chimerism.90%. In MA, multivari-
ate analysis found that patients with more prior chemotherapy (p 5
0.05) and peripheral stem cells (p5 0.008) were more likely to reach
chimerism.90%. These data demonstrated that T-cell engraftment
occurred more quickly in NMA thanMA transplants using busulfan.
Factors predictive of T-cell engraftment kinetics were similar in
NMA and MA transplantation. The preparative regimen is only
one of many factors determining the kinetics of T-cell engraftment.
Designation of a regimen as myeloablative does not correlate with
more rapid or complete T-cell engraftment.
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PRE-EMPTIVE TREATMENTWITH CIDOFOVIR FOR SYMPTOMATIC BK VI-
RUS POSITIVE PATIENTS WHO UNDERWENT ALLOGENEIC STEM CELL
TRANSPLANT REDUCES THE RISK OF PROGRESSION TO HEMORRHAGIC
CYSTITIS
Bilodeau, A., Phillips, J., Mapara, M., Raptis, A., Hou, J.-Z., Agha, M.
Univ. of Pittsburgh Medical Center, Pittsburgh, PA
We have previously demonstrated that Polyomavirus BK asso-
ciated hemorrhagic cystitis is becoming an increasingly recog-
nized complication of HSCT. Our previously published
retrospective analysis demonstrated that BKV was observed in
48% of patients undergoing an allogeneic stem cell transplant
and 16% of them developed hemorrhagic cystitis. Based on therecent findings, we designed a prospective protocol for pre-emp-
tive treatment with Cidofovir for symptomatic BK Viruria. 39
patients underwent an allogeneic stem cell transplant from either
an HLA-matched sibling or unrelated donor during fiscal year
2008. Patients who manifested urological symptoms received Ci-
dofovir 375mg IV QOW until all symptoms resolved. Out of 39
of these patients, 59% (23/39) developed BK virus infection
determined using quantitative real-time PCR assay. Out of these
23 patients, 61% (14/23) received a myeloablative conditioning
regimen (Bu/Cy, TBI/Cy) and 39% (9/23) a non myeloablative
(Flu/TBI, Flu/Cy/Rituxan, Cy/ATG/TBI, TBIx1, Flu/Mel/
Campath, Flu/Cy/TBI). 30% (7/23) became symptomatic and
subsequently received Cidofovir 375mg IV QOW which was
continued until all symptoms resolved and 71% (5/7) also re-
ceived Ciprofloxacin. 57% (4/7) had Graft Versus Host Disease
and 86% (6/7) were concurrently receiving high dose steroid
therapy. 71% (5/7) developed mild hematuria and 29% (2/7) de-
veloped small thrombus in the urine. The mean of total Cidofo-
vir doses received was three and the two patients who developed
mild hematuria with thrombus received 5 and 6 doses respec-
tively. Bone marrow suppression was noted in three patients
who received Cidofovir which was consequently either held or
completely discontinued. All 7 patients had complete resolution
of symptoms, and none developed any clinical manifestations of
hemorrhagic cystitis defined as gross hematuria or the need of
continuous bladder irrigation. There was no correlation with
symptoms and BK virus PCR titers. In conclusion, pre-emptive
treatment of symptomatic BK Viruria with Cidofovir in the allo-
geneic stem cell transplant setting is safe and effective and poten-
tially prevents the progression to BK virus induced hemorrhagic
cystitis.281
GERIATRIC ASSESSMENT (GA) MAY IDENTIFY VULNERABLE OLDER
ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION (HCT) RECIPI-
ENTS
Swanson, K.1, van Besien, K.1, Extermann, M.2, Rich, E.1, Stock, W.1,
Larson, R.1, Artz, A.1 1University of Chicago; 2University of Florida,
Moffitt Cancer Center
Comorbidity indices and performance status (PS) have been the
primary tools used to predict HCT tolerance; however, these tools
suffer from poor discriminative capacity. Geriatric Assessment
(GA) has found widespread application to assess reduced physio-
logic reserve (i.e. vulnerability) among elderly adults. We hypoth-
esized that a modified GA would identify vulnerable HCT
recipients 50 years and older. We supplemented the standard
pre-HCT evaluation (e.g. history, laboratory, PFT’s) with a pro-
spective GA integrating multiple geriatric domains. Among 94 pa-
tients (pts) 50 years and older, 91 consented to the GA. The
median age was 58 (range 50 – 72). Conditioning regimens were
primarily fludarabine/melphalan, fludarabine/busulfan, and clo-
farabine/melphalan with alemtuzumab and tacrolimus for immu-
nosuppression. The comorbidity domain was scored using four
tools: Charlson Comorbidity Index (CCI), Kaplan Feinstein Scale
(KF), Hematopoietic Cell Transplantation-Comorbidity Index
(HCT-CI) and the Cumulative Illness Rating Scale-Geriatric
(CIRS-G). Functional domains were estimated by PS, frailty index
(FI), and the physical health portion of the short form 36 (SF36-
PH) whereas the mental health portion of the SF36 (SF36-MH)
measured mental health. Activities of daily living (ADL) and in-
strumental ADL (IADL) assessed disability. Table 1 describes
the results and variation detected by each tool within each geriat-
ric domain. For comorbidity, the CIRS-G was the most sensitive
tool as every pt showed comorbidity. Among functional measures,
PS was normal (i.e. PS 5 0) in most pts (64%). Only 4% had a PS
of 2. In contrast, the FI and SF36-PH demonstrated functional
limitations in the majority of pts. Specifically, 52% were
‘‘pre-frail’’ (FI of 1 – 2) and 29% were frail (FI of 3–5). Disability
by ADL or IADL was rare. A modified GA in older HCT recipi-
ents is feasible and may reveal abnormalities in multiple geriatric
domains suggesting vulnerability not recognized by a standard
evaluation. Ongoing studies will determine the predictive validity
of specific domains within the GA.
Poster Session-II 103Table 1. Results from a Prospective Geriatric Assessment
Before Allogeneic HCT for Recipients 50 years and over
Reference Interquartile
Predictor (Normal) Median Mean SD Range RangeComorbidity
CCI 0 0 0.49 0.73 0–3 0–1
KF 0 1 0.88 0.84 0–3 0–1
HCT-CI 0 3 2.8 2.00 0–9 1–4
CIRS-G 0 8 8.23 3.24 2–16 6–10Functional
ECOG PS 0 0 0.4 0.58 0–2 0–1
Frailty Index 0 2 1.79 1.25 0–5 1–3
SF36-PH 100 52 53 18.81 16–100 38–65Mental Health
SF36-MH 100 66 65 163.41 23–100 55–73Disability
ADL 12 12 11.89 0.41 9–12 12–12
IADL 14 14 13.15 1.76 4–14 13–14SD-Standard deviation282
HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR INHERITED
METABOLIC DISEASES: AN OVERVIEW OF LONG-TERM OUTCOMES IN A
SINGLE PEDIATRIC CENTRE
Gassas, A.1, Raiman, J.2, White, L.1, Finkelstein-Schechter, T.1,
Clarke, J.2, Doyle, J.1 1Hospital for Sick Children, Toronto, ON, Canada;
2Hospital for Sick Children
Over the past two decades, hematopoietic stem cell transplanta-
tion (HSCT) has been utilized as effective therapy for selected
inherited metabolic diseases (IMD’s). The primary objective of
HSCT for these disorders has been to promote long-term survival,
optimize quality of life and improve neuro-cognitive performance.
Between 1990–2007, in the Hospital for Sick Children in Toronto,
Canada, we performed 39 HSCT’s for IMD’s (10 related and 29
unrelated); 22 HSCT’s for 21 children with Hurler syndrome, 8
for malignant infantile osteopetrosis, 6 for X- linked adrenoleuko-
dystrophy (ALD), 2 for Gaucher’s syndrome, 1 for gangliosidosis,
1 for sialiosis type 1 and 1HSCT forNeiman-Pick type 1A. Busulfan
(BU), cylophosphamide (CY) and single dose (300cGy) total body
irradiation (TBI) were used as a conditioning regimen in 33 patients
and 6 patients, in recent years of the study, received BU/CY and thy-
moglobulin. At amedian follow up of 5.6 years (range 1.3–15.6 years)
18/21 patients with Hurler syndrome are alive. Educational status
was determined in 16 of them; 14 attended regular schools, some
with educational assistants, 1 attended a special needs school and 1
attended day-care. As of the last follow-up, 13/18 were ambulatory,
2 had some mobility difficulties and 1 was wheelchair-bound. For
non-Hurler’s, two children, 1 with osteopetrosis and 1 with ALD
suffered secondary graft failure and died from progressive disease.
The remaining children with osteopetrosis are alive and most chil-
dren attended regular school or education for the visually handi-
capped. One out of the five survivors with ALD has been
transferred to the adult follow up clinic and he is in full time employ-
ment. The patient with Neiman Pick type 1A progressed despite
durable engraftment.
Conclusion: These findings confirm that results and long-term
follow up of allogeneic HSCT in these serious and lethal IMD’s
are very encouraging and long term, independent and meaningful
survival, is possible.283
VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGFA) GENE POLYMOR-
PHISMS MAY PREDICT THE RISK OF ACUTE GRAFT-VERSUS-HOST
DISEASE FOLLOWING ALLOGENEIC TRANSPLANTATION: PREVENTIVE
EFFECT OF VEGF ON ACUTE GVHD
Kim, D.H.1, Lee, N.Y.2, Lee,M.-H.2, Sohn, S.K.2, Jang, J.H.1, Kim, K.1,
Jung, C.W.1 1Samsung Medical Center, Seoul, Korea; 2Kyungpook
National University Hospital, Daegu, Korea
Background: Microvessel injury is associated with the develop-
ment of graft-versus-host disease (GVHD), whereas high levels ofpost-transplant vascular endothelial growth factor (VEGF) have
a protective effect on severe acute GVHD (aGVHD) and trans-
plant-related mortality. The current study aimed to determine the
impact of VEGFA gene single nucleotide polymorphisms (SNPs)
on the risk of acute GVHD following allogeneic stem cell transplan-
tation (SCT).
Methods: Four VEGF gene SNPs were analyzed in 98 recipi-
ents using PCR/RFLP, i.e., –2578 C.A (rs699947), –460 T.C
(rs833061), 1405 G.C (rs2010963) and 1936 C.T
(rs3025039).
Results: Strong linkage disequilibrium was noted between loci
–2578, –460 and1405, but not between these and1936. Accordingly,
4 haplotypes were generated based on the genotypes of –2578, –460,
and 1405 as follows: CTC (47.9%), CTG (26.7%), ACG (24.2%),
and CCC (1.0%). The group with low producibility of VEGF (i.e.,
1936CT genotype and 2 copies of the ACG haplotype) showed
a higher incidence of acute GVHD: A significant association was
noted between the risk of grade 2–4 aGVHD and the 1 936 CT
(p 5 0.006), the –2578 AA (p 5 0.003), and the –460 CC
(p5 0.002) genotypes, and the ACG haplotype (p5 0.003). No asso-
ciation was observed between the VEGFA gene SNPs and chronic
GVHD.
Conclusion: The VEGFA gene SNPs might predict a lower risk
of acute GVHD. The current result suggests that VEGF might
play a protective role in the pathogenesis of acute GVHD.284
HIGHER INCIDENCE OF CMV REACTIVATION IN CMV SEROPOSITIVE
RECIPIENTS FOLLOWING FLUDARABINE BASED REDUCED INTENSITY
CONDITIONING TRANSPLANTS – A RETROSPECTIVE COMPARISON
WITH MYELOABLATIVE TRANSPLANTS
George, B.1, Gillroy, N.2, Kerridge, I.1, Gottlieb, D.1, Hertzberg, M.1,
Bradstock, K.1 1Westmead Hospital, Sydney, NSW, Australia; 2West-
mead Hospital, Sydney, NSW, Australia
Limited data exists on the incidence of Cytomegalovirus
(CMV) reactivation following fludarabine based reduced inten-
sity conditioning (RIC) transplants. A retrospective cohort study
was performed of high risk patients (CMV seropositive recipient
with either positive/negative donor) undergoing RIC or myeloa-
blative transplants (MAT), between January 2001 and June 2008,
to compare rates and risk factors for CMV reactivation. All sero-
positive recipients received pre-transplant ganciclovir followed
by valaciclovir as herpes virus prophylaxis. No post transplant
ganciclovir prophylaxis was given. Weekly monitoring for
CMV was done using qualitative PCR; if positive, quantification
was done using either pp65 antigenemia or quantitative PCR
(COBAS R). Eighty three RIC transplants (21 unrelated) and
127MAT (48 unrelated) were performed during the study period.
The median age of RIC transplants (51 males; 32 females) was 49
years (range: 18–65) compared to 39 years (17–62) with MAT (72
males; 55 females). Anti-thymocyte globulin (ATG) or Alemtu-
zumab (Campath) was used for T cell depletion in 44 MAT
(34.6%) and 29 RIC transplants (34.9%) [p 5 1.000]. Acute graft
versus host disease (GVHD) was observed in 50.6% of RIC and
66.1% of MAT [p 5 0.030]. CMV reactivation was seen in 53
RIC transplants (63.8%) at a median of 47 days (range: 24 –
1977) and 61 MAT transplants (48% [p 5 0.030]) at a median
of 47 days (22 – 187) post transplant. Five reactivations each oc-
curred in the RIC (9.4%) and the MAT group (8.2%) beyond Day
100. CMV reactivation was higher with RIC transplants both in
the presence (73.8% vs 61.9%; p 5 0.230) and absence of
GVHD (53.6% vs 26.4%; p 5 0.003). Reactivation rates were
similar for unrelated donors (71.4% in RIC vs 62.5% in MAT;
p 5 0.586) but significantly higher in RIC with sibling donors
(61.2% vs 39.2% p 5 0.011). The use of ATG during condition-
ing did not influence reactivation. Of the 15 RIC transplants that
received Campath, 11 had CMV reactivation. The overall
incidence of CMV disease was 9.6% following RIC and 6.2%
following MAT (p 5 0.429). The higher incidence of CMV reac-
tivation and disease in RIC transplants highlights the need
for improved prophylactic and preemptive strategies,
potentially including the use of CMV specific CTL in this
vulnerable population.
